AbbVie Inc (WBO:ABBV)
€ 148.62 -1.44 (-0.96%) Market Cap: 264.38 Bil Enterprise Value: 316.20 Bil PE Ratio: 47.40 PB Ratio: 35.22 GF Score: 91/100

Abbvie Inc at JPMorgan Healthcare Conference Transcript

Jan 15, 2020 / 03:30PM GMT
Release Date Price: €80.4 (+1.52%)
Christopher Thomas Schott
JP Morgan Chase & Co, Research Division - Senior Analyst

Good morning, everybody. I'm Chris Schott from JPMorgan and pleased to be hosting a fireside chat today with the AbbVie management team. From the company, we have Rick Gonzalez, Chairman and CEO.

Richard A. Gonzalez
AbbVie Inc. - Chairman & CEO

Good morning.

Christopher Thomas Schott;Richard A. Gonzalez
JP Morgan Chase & Co, Research Division - Senior Analyst;AbbVie Inc. - Chairman &

Mike Severino, President of AbbVie; and Rob Michael, the CFO. Thanks for joining us. Obviously, a pretty exciting time for the company.

Before we kick it off, I did want to mention, given the pending Allergan transaction, we're not going to be having a breakout session post the fireside today.

So with that, Rick, did you want to make some opening remarks as we think about kind of the new AbbVie as we look towards the Allergan close, and then we can jump into a discussion from there?

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot